FHI selected as preferred provider to a consortium of product development partnerships
RESEARCH TRIANGLE PARK, NC — FHI has been selected as one of six preferred providers offering their clinical research expertise to a consortium of 14 global health Product Development Partnerships (PDPs). The consortium of PDPs is working to develop and deliver affordable treatments and vaccines that will help improve the lives of some of the world's most vulnerable people.
FHI's forty years of research experience has focused on a multitude of infectious and neglected diseases, such as HIV, HSV, HPV, other sexually transmitted diseases, malaria, and seasonal and pandemic influenza. FHI has strong history delivering the highest quality research in resource constrained settings and has been recognized globally for its leadership in the ethical treatment of trial participants.
"This consortium has the potential to find cures for the most widespread diseases, like tuberculosis, malaria, influenza, dengue fever, HIV and Chagas disease," said Albert J. Siemens, FHI Chairman and Chief Executive Officer. "FHI is honored to be selected as a preferred provider, offering our expertise and experience to the critical work being undertaken by the PDPs."
The consortium members are funded, in part, by the Bill & Melinda Gates Foundation. This preferred provider agreement offers consortium members an opportunity to work with pre-qualified organizations, including FHI, thereby consolidating resources, and achieving heightened efficiencies while maintaining the highest standards. The synergies and efficiencies of partnering with the preferred providers are expected to be significant.
FHI partners with government, non-governmental, and private sector entities on major pharmaceutical and biotechnology clinical trials worldwide.